title: Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.
abstract: Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. Most patients have an atopic predisposition. The definitive diagnosis of AD requires the presence of all three features: (i) pruritus; (ii) typical morphology and distribution of the eczema; and (iii) chronic and chronically relapsing course. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.
authors.affiliation: Department of Dermatology, Graduate School of Medicine, Nihon Medical School, Tokyo, Japan.
authors.forename: Hidehisa
authors.initials: H
authors.lastname: Saeki
authors.affiliation: Division of Skin Surface Sensing, Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nakahara
authors.affiliation: Department of Dermatology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
authors.forename: Akio
authors.initials: A
authors.lastname: Tanaka
authors.affiliation: Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Kabashima
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Sugaya
authors.affiliation: Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Murota
authors.affiliation: Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Ebihara
authors.affiliation: Department of Dermatology, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Japan.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Kataoka
authors.affiliation: Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
authors.forename: Michiko
authors.initials: M
authors.lastname: Aihara
authors.affiliation: Division of Dermatology, Tokyo Teishin Postal Services Agency Hospital, Tokyo, Japan.
authors.forename: Takafumi
authors.initials: T
authors.lastname: Etoh
authors.affiliation: Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan. nkatoh@koto.kpu-m.ac.jp.
authors.forename: Norito
authors.initials: N
authors.lastname: Katoh
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000097:blood / Q000145:classification / Q000175:diagnosis / Q000628:therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004035:Diet Therapy / Q000379:methods; D019317:Evidence-Based Medicine; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006633:Histamine Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007564:Japan; D009824:Ointments; D010349:Patient Compliance; D010353:Patient Education as Topic; D011537:Pruritus / Q000628:therapy*; D011788:Quality of Life; D012720:Severity of Illness Index; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014467:Ultraviolet Therapy / Q000379:methods
chemical_list: D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D005938:Glucocorticoids; D006633:Histamine Antagonists; D007166:Immunosuppressive Agents; D009824:Ointments; D016559:Tacrolimus
keywords: atopic dermatitis; clinical practice guideline; diagnosis; evidence-based medicine; treatment